Ku0060648

shRNAs pLKO.1 lentiviral plasmids used for non-targeting shRNA control (SHC002) and human PRKDC knockdown were purchased from Sigma. The shRNA clones used for targeting PRKDC were TRCN0000197152 (shPRKDC#1), TRNC0000196328 (shPRKDC#2), TRCN0000195491 (shPRKDC#3), TRCN0000194985 (shPRKDC#4) and TRCN0000194719 (shPRKDC#5). Non-targeting control shRNA and three PRKDC shRNAs (shPRKDC#1, shPRKDC#3 and shPRKDC#5) were cloned into the inducible pLKO-Tet-On puromycin vector as previously described [26 (link)]. pCDH-CMV-MCS-EF1-Puro lentivector was purchased from System Bioscience. pCDH-c-MYC, pCDH-L-MYC1, pCDH-L-MYC2 and pCDH-N-MYC vectors were generated by cloning protein coding sequences of human c-MYC, L-MYC isoform1, L-MYC isoform2 and N-MYC into pCDH-CMV-MCS-EF1-Puro lentivector. Etoposide, NU-7441, and KU0060648 were obtained from Sigma (cat# E1383), Tocris Cookson Inc. (cat# 3712), and Axon Medchem BV (cat# Axon 1584), respectively. The proteasome inhibitor, MG132, was obtained from Sigma (cat#C2211).

AZ31, AZ20, AZD2281, AZD2811, AZD7648, TLR1 (WO2014183850), M9831/VX-984, FEN-IN-1, PolQi1 (WO2021/028643, Example 158), PolQi2 (WO2020/243459, Example 99) were provided by AstraZeneca (Gothenburg, SE). Three of the DNA-PK inhibitors, AZD7648 (HY-111783, MedChemExpress), M9831/VX-984 (HY-19939S, MedChemExpress) and M3814 (S8586, Selleckchem) are commercially available. Nu7026 and KU0060648 were purchased from Sigma-Aldrich (N1537, SML1257). Novobiocin, ART558 and AZD7648 were obtained from MedChemExpress (HY-B0425A, HY-141520 and HY-111783). SCR7 was purchased from Selleckchem (S7742). All compounds were dissolved in DMSO (Thermo Fisher Scientific) at a concentration of 10 mM.